Exploiting Cancer Cell Vulnerabilities to Develop a Combination Therapy for Ras-Driven Tumors

被引:207
作者
De Raedt, Thomas [1 ,2 ,3 ]
Walton, Zandra [2 ,4 ]
Yecies, Jessica L. [2 ,5 ]
Li, Danan [2 ,4 ]
Chen, Yimei [6 ]
Malone, Clare F. [1 ,2 ]
Maertens, Ophelia [1 ,2 ]
Jeong, Seung Min [7 ]
Bronson, Roderick T. [2 ]
Lebleu, Valerie [2 ,8 ]
Kalluri, Raghu [2 ,8 ]
Normant, Emmanuel [9 ]
Haigis, Marcia C. [7 ]
Manning, Brendan D. [2 ,5 ]
Wong, Kwok-Kin [1 ,2 ,3 ]
Macleod, Kay F. [6 ]
Cichowski, Karen [1 ,2 ,3 ]
机构
[1] Brigham & Womens Hosp, Dept Med, Div Genet, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Boston, MA 02115 USA
[3] Dana Farber Harvard Canc Ctr, Ludwig Ctr, Boston, MA 02115 USA
[4] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[5] Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, Boston, MA 02115 USA
[6] Univ Chicago, Ben May Inst Canc Res, Chicago, IL 60637 USA
[7] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA
[8] Beth Israel Deaconess Med Ctr, Div Matrix Biol, Boston, MA 02115 USA
[9] Infin Pharmaceut, Cambridge, MA 02139 USA
关键词
ENDOPLASMIC-RETICULUM-STRESS; UNFOLDED PROTEIN RESPONSE; NEUROFIBROMATOSIS TYPE-1 GENE; OXIDATIVE STRESS; LUNG-CANCER; MUTATIONS; AUTOPHAGY; HSP90; SUPPRESSOR; REVEALS;
D O I
10.1016/j.ccr.2011.08.014
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Ras-driven tumors are often refractory to conventional therapies. Here we identify a promising targeted therapeutic strategy for two Ras-driven cancers: Nf1-deficient malignancies and Kras/p53 mutant lung cancer. We show that agents that enhance proteotoxic stress, including the HSP90 inhibitor IPI-504, induce tumor regression in aggressive mouse models, but only when combined with rapamycin. These agents synergize by promoting irresolvable ER stress, resulting in catastrophic ER and mitochondrial damage. This process is fueled by oxidative stress, which is caused by IPI-504-dependent production of reactive oxygen species, and the rapamycin-dependent suppression of glutathione, an important endogenous antioxidant. Notably, the mechanism by which these agents cooperate reveals a therapeutic paradigm that can be expanded to develop additional combinations.
引用
收藏
页码:400 / 413
页数:14
相关论文
共 52 条
[1]   Autophagy: assays and artifacts [J].
Barth, Sandra ;
Glick, Danielle ;
Macleod, Kay F. .
JOURNAL OF PATHOLOGY, 2010, 221 (02) :117-124
[2]  
BETSEY MA, 1973, B WORLD HEALTH ORGAN, V48, P1
[3]   A MAJOR SEGMENT OF THE NEUROFIBROMATOSIS TYPE-1 GENE - CDNA SEQUENCE, GENOMIC STRUCTURE, AND POINT MUTATIONS [J].
CAWTHON, RM ;
WEISS, R ;
XU, GF ;
VISKOCHIL, D ;
CULVER, M ;
STEVENS, J ;
ROBERTSON, M ;
DUNN, D ;
GESTELAND, R ;
OCONNELL, P ;
WHITE, R .
CELL, 1990, 62 (01) :193-201
[4]   Comprehensive genomic characterization defines human glioblastoma genes and core pathways [J].
Chin, L. ;
Meyerson, M. ;
Aldape, K. ;
Bigner, D. ;
Mikkelsen, T. ;
VandenBerg, S. ;
Kahn, A. ;
Penny, R. ;
Ferguson, M. L. ;
Gerhard, D. S. ;
Getz, G. ;
Brennan, C. ;
Taylor, B. S. ;
Winckler, W. ;
Park, P. ;
Ladanyi, M. ;
Hoadley, K. A. ;
Verhaak, R. G. W. ;
Hayes, D. N. ;
Spellman, Paul T. ;
Absher, D. ;
Weir, B. A. ;
Ding, L. ;
Wheeler, D. ;
Lawrence, M. S. ;
Cibulskis, K. ;
Mardis, E. ;
Zhang, Jinghui ;
Wilson, R. K. ;
Donehower, L. ;
Wheeler, D. A. ;
Purdom, E. ;
Wallis, J. ;
Laird, P. W. ;
Herman, J. G. ;
Schuebel, K. E. ;
Weisenberger, D. J. ;
Baylin, S. B. ;
Schultz, N. ;
Yao, Jun ;
Wiedemeyer, R. ;
Weinstein, J. ;
Sander, C. ;
Gibbs, R. A. ;
Gray, J. ;
Kucherlapati, R. ;
Lander, E. S. ;
Myers, R. M. ;
Perou, C. M. ;
McLendon, Roger .
NATURE, 2008, 455 (7216) :1061-1068
[5]   Mouse models of tumor development in neurofibromatosis type 1 [J].
Cichowski, K ;
Shih, TS ;
Schmitt, E ;
Santiago, S ;
Reilly, K ;
McLaughlin, ME ;
Bronson, RT ;
Jacks, T .
SCIENCE, 1999, 286 (5447) :2172-2176
[6]  
Dancey Janet E, 2009, Semin Oncol, V36 Suppl 3, pS46, DOI 10.1053/j.seminoncol.2009.10.010
[7]   Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors [J].
Dasgupta, B ;
Yi, YJ ;
Chen, DY ;
Weber, JD ;
Gutmann, DH .
CANCER RESEARCH, 2005, 65 (07) :2755-2760
[8]   ABNORMAL REGULATION OF MAMMALIAN P21(RAS) CONTRIBUTES TO MALIGNANT-TUMOR GROWTH IN VONRECKLINGHAUSEN (TYPE-1) NEUROFIBROMATOSIS [J].
DECLUE, JE ;
PAPAGEORGE, AG ;
FLETCHER, JA ;
DIEHL, SR ;
RATNER, N ;
VASS, WC ;
LOWY, DR .
CELL, 1992, 69 (02) :265-273
[9]   Anti-oncogenic role of the endoplasmic reticulum differentially activated by mutations in the MAPK pathway [J].
Denoyelle, Christophe ;
Abou-Rjaily, George ;
Bezrookove, Vladimir ;
Verhaegen, Monique ;
Johnson, Timothy M. ;
Fullen, Douglas R. ;
Pointer, Jenny N. ;
Gruber, Stephen B. ;
Su, Lyndon D. ;
Nikiforov, Mikhail A. ;
Kaufman, Randal J. ;
Bastian, Boris C. ;
Soengas, Maria S. .
NATURE CELL BIOLOGY, 2006, 8 (10) :1053-U24
[10]   Somatic mutations affect key pathways in lung adenocarcinoma [J].
Ding, Li ;
Getz, Gad ;
Wheeler, David A. ;
Mardis, Elaine R. ;
McLellan, Michael D. ;
Cibulskis, Kristian ;
Sougnez, Carrie ;
Greulich, Heidi ;
Muzny, Donna M. ;
Morgan, Margaret B. ;
Fulton, Lucinda ;
Fulton, Robert S. ;
Zhang, Qunyuan ;
Wendl, Michael C. ;
Lawrence, Michael S. ;
Larson, David E. ;
Chen, Ken ;
Dooling, David J. ;
Sabo, Aniko ;
Hawes, Alicia C. ;
Shen, Hua ;
Jhangiani, Shalini N. ;
Lewis, Lora R. ;
Hall, Otis ;
Zhu, Yiming ;
Mathew, Tittu ;
Ren, Yanru ;
Yao, Jiqiang ;
Scherer, Steven E. ;
Clerc, Kerstin ;
Metcalf, Ginger A. ;
Ng, Brian ;
Milosavljevic, Aleksandar ;
Gonzalez-Garay, Manuel L. ;
Osborne, John R. ;
Meyer, Rick ;
Shi, Xiaoqi ;
Tang, Yuzhu ;
Koboldt, Daniel C. ;
Lin, Ling ;
Abbott, Rachel ;
Miner, Tracie L. ;
Pohl, Craig ;
Fewell, Ginger ;
Haipek, Carrie ;
Schmidt, Heather ;
Dunford-Shore, Brian H. ;
Kraja, Aldi ;
Crosby, Seth D. ;
Sawyer, Christopher S. .
NATURE, 2008, 455 (7216) :1069-1075